Streetbeat News

Revenues

TEX

Analysts have recently updated their ratings and price targets for Terex (NYSE:TEX), with 7 analysts offering views ranging from bullish to bearish. Over the past three months, sentiments have shifted, with the current average 12-month price target at $60.57, down from the previous $67.71. Analysts from firms including Jefferies, UBS, Goldman Sachs, Barclays, JP Morgan, and Citigroup have lowered their price targets, reflecting changes in market dynamics and company performance. Terex has shown strong financial performance with solid revenue growth, high net margin, and impressive ROE and ROA, while maintaining a balanced debt approach.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 1:00 pm

JBLU

JSX, backed by JetBlue Airways (NASDAQ:JBLU), has placed an order for up to 332 hybrid-electric aircraft from various manufacturers, with deliveries starting in 2028. The order includes the Heart Aerospace ES-30, Aura Aero Era, and Electra eSTOL aircraft. JSX aims to serve over 2000 airports, reducing travel costs and carbon emissions. The confirmed order is for 132 aircraft, with the rest as options.

Portfolio Pulse from Anan Ashraf

December 20, 2023 | 12:46 pm

BABA

PDD

Alibaba Group Holding Ltd (NYSE:BABA) is restructuring, with Eddie Wu replacing Trudy Dai to head Tmall and Taobao. Dai will manage a new entity for Alibaba's global investment assets. Amidst challenges from regulatory scrutiny and rising competition from PDD Holdings Inc (NASDAQ:PDD) and ByteDance Ltd, Alibaba is refocusing on core businesses and considering divestitures. Analysts have rerated BABA due to slow turnaround and cloud business spinoff withdrawal. Alibaba reversed a prior decision to split into six divisions and is now led by Wu, with Joseph Tsai overseeing potential asset divestitures. Additionally, BWB Inc has filed patent infringement lawsuits against Alibaba in multiple countries. Alibaba's stock has declined by over 18% YTD, while PDD's stock has risen by 78%. BABA's premarket trading shows a slight increase of 0.27% to $75.60.

Portfolio Pulse from Anusuya Lahiri

December 20, 2023 | 12:36 pm

GIS

General Mills has updated its FY24 outlook, now expecting a 4-5% increase in adjusted operating profit and adjusted EPS in constant currency, a slight decrease from the previously forecasted 4-6% growth. The company anticipates the economic health of consumers, input cost inflation, and supply chain stability to be key factors affecting its performance. General Mills still projects a 5% input cost inflation, largely due to labor inflation affecting sourcing, manufacturing, and logistics.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:07 pm

GIS

General Mills has updated its fiscal year 2024 topline outlook, now expecting organic net sales to be between a 1% decline and flat, compared to the previously forecasted 3-4% growth. This revision is due to a slower volume recovery than anticipated.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:04 pm

TAK

Takeda Pharmaceutical Company has secured a two-year contract with Canadian Blood Services for the supply of GLASSIA, a treatment for a rare form of emphysema. This deal may positively impact Takeda's revenues and market presence in Canada.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:04 pm

FND

Floor & Decor Holdings (NYSE:FND) has received mixed analyst ratings over the past quarter, with 14 analysts offering diverse opinions. The average 12-month price target is now $91.86, down 11.67% from the previous $104.00. Analysts have adjusted their ratings and price targets, with some raising and others lowering their expectations. The company operates in the hard surface flooring market and has shown strong revenue growth and net margin, but its ROE is below industry average. Its debt-to-equity ratio is favorable compared to the industry.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 12:01 pm

MRTX

Mirati Therapeutics (NASDAQ:MRTX) has received mixed analyst ratings over the past quarter, with 11 analysts offering diverse opinions. The average 12-month price target for MRTX is $64.09, with a high estimate of $83.00 and a low of $58.00, reflecting a 7.34% increase from the previous target of $59.71. Analysts from Citigroup, Leerink Partners, Stifel, Piper Sandler, B. Riley Securities, Scotiabank, Jefferies, BMO Capital, and JMP Securities have adjusted their ratings and price targets, indicating a range of expectations for the company's performance. Mirati Therapeutics, a clinical-stage oncology company, has shown a revenue growth rate of 201.97% as of September 30, 2023, but struggles with a net margin of -987.22% and an ROA of -15.84%, despite a strong ROE of -19.33% and a low debt-to-equity ratio of 0.05.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 12:00 pm

PCRX

Pacira BioSciences (NASDAQ:PCRX) was analyzed by 7 analysts, showing a mix of bullish and somewhat bullish ratings, with no bearish or indifferent stances. The average 12-month price target is $52.71, down from $58.40. Analysts from firms like Raymond James, HC Wainwright & Co., Piper Sandler, RBC Capital, Needham, and Barclays have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Pacira BioSciences, known for its non-opioid pain management solutions, has seen a -2.11% revenue decline as of September 30, 2023, but outperforms in net margin and ROE, with a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 12:00 pm

YOU

Clear Secure (NYSE:YOU) received mixed analyst ratings in the latest quarter, with 3 bullish and 1 somewhat bearish. The average 12-month price target is $27.75, up from $24.00, with a high estimate of $40.00 and a low of $20.00. Analysts from Wells Fargo, Needham, and Goldman Sachs provided recent evaluations, with Goldman Sachs raising its target from $24.00 to $27.00. Clear Secure has shown strong financial health with a 38.36% revenue growth rate, a net margin of 9.57%, an ROE of 5.65%, an ROA of 1.43%, and a low debt-to-equity ratio of 0.47.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 12:00 pm